However, GLUT expression modulation can also be an important therapeutic target, e.g., in AD, GLUT1/3 upregulation may prevent the disease progression, and in stroke, GLUT1/3 upregulating treatment may have the potential to improve the final outcome faster. This evidence concerns the gene SLC2A1 and stroke disorder.